Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety
Year: 2021
Type: article
Abstract: Introduction: Regional or distant metastases from melanoma may be surgically resected but remain at high-risk of recurrence. Over the last few years, several treatments have been approved to mitigate this risk. These include anti-PD-1 agents, specifically pembrolizumab and nivolumab.Areas covered: Herein, we will discuss the landscape of pembrolizumab safety and efficacy used in the adjuvant setting for high-risk, resected melanoma. We place this in context with other available adjuvant therapies, and discuss subgroup analyses.Expert opinion: Anti-PD-1 therapy with either pembrolizumab or nivolumab has become a standard of care for patients with resected stage III or IV melanoma. In our practice, we generally offer these agents (which have comparable safety and efficacy profiles) to patients with resected stage IIIb–IV melanoma regardless of BRAF mutation status.
Authors: Caroline A. Nebhan, Douglas B. Johnson
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Predicting and profiling long-term survival after immune checkpoint inhibition, Investigating concurrent Ras-pathway inhibition to optimize response to anti-PD-1 therapy in NRAS-mutant melanoma, VOLT (Vanderbilt Oncology Training Program), Long-Term Cardiovascular Sequelae of Cancer Immunotherapies
OpenAlex ID: W3123364915